Login
$ADPT
$27.87 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Chad Robins Also a director
Chief Executive Officer and Chairman
51 Not stated Not stated $9,081,690
Kyle Piskel
Chief Financial Officer
42 Since 2024
2 years
2015 $3,310,729
Julie Rubinstein
President and Chief Operating Officer
54 Not stated Not stated $4,603,995
Francis Lo
Chief People Officer
45 Since 2019
7 years
Not stated Not reported
Harlan Robins
Chief Scientific Officer
53 Not stated Not stated $8,509,575
Susan Bobulsky
Chief Commercial Officer, MRD
45 Since 2024
2 years
2014 $3,547,558
Sharon Benzeno
Chief Commercial Ofc Imm Med
Title from the Form 4 dated Jun 26, 2026
52 Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
5
serving now
Independent
4 of 4
stated in the proxy; 1 not stated
Average tenure
9.5 years
from year joined
Director On board Independent Committees Other public boards 2025 pay Source
Chad Robins
Not stated Not stated None stated None stated Paid as CEO
Peter Neupert
2013
13 years
Independent
Nominating and Corporate Governance Committee · Chair
Laboratory Corporation of America Holdings $354,997
Robert Hershberg
2013
13 years
Independent
Compensation and Human Capital Committee · Chair Nominating and Corporate Governance Committee
Hillevax, Inc., Recursion Pharmaceuticals, Inc. $324,997
Katey Owen
2021
5 years
Independent
Audit Committee Compensation and Human Capital Committee
None stated $309,997
Michelle Griffin
2019
7 years
Independent None stated None stated $329,997

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

7 disclosed in the proxy filed Apr 24, 2026
Viking Global Entities
beneficially owns more than 5% of our common stock
Amount not stated
May 30, 2019

Seventh amended and restated investors rights agreement providing registration, information, first offer and first refusal rights; most rights terminated at IPO.

With certain purchasers of our capital stock Open in proxy
$35,725 each
March 2021

Purchased 250,000 shares of DigitalBio common stock (2.5% interest) in March 2021.

With Digital Biotechnologies, Inc. Open in proxy
Harlan Robins, PhD
$35,725 each
March 2021

Purchased 250,000 shares of DigitalBio common stock (2.5% interest) in March 2021.

With Digital Biotechnologies, Inc. Open in proxy
Julie Rubinstein
$71,450
March 2021

Purchased 500,000 shares of DigitalBio common stock (5% interest) in March 2021.

With Digital Biotechnologies, Inc. Open in proxy
family trusts related to Mr. and Dr. Robins
trusts related to Mr. Robins and Dr. Robins
$285,800
March 2021

Purchased an aggregate of 2,000,000 shares of DigitalBio common stock (20% interest) in March 2021.

With Digital Biotechnologies, Inc. Open in proxy
Julie Rubinstein and family trusts related to Mr. Robins, Dr. Robins and Ms. Rubinstein
Amount not stated
December 2025 through February 2026

Participated in DigitalBio Series A Preferred Stock financing, purchasing an aggregate of 557,142 shares (about 4% of DigitalBio).

With Digital Biotechnologies, Inc. Open in proxy
directors and certain executive officers
directors and certain executive officers of the company
Amount not stated

Indemnification agreements requiring the company to indemnify directors and certain executive officers for expenses, judgments, fines and settlements.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support